Drug Profile


Alternative Names: BC-3781; BC-3781.Ac; Lefamulin-acetate

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nabriva Therapeutics
  • Class Alkenes; Antibacterials; Cyclopentanes; Diterpenes; Polycyclic compounds; Small molecules; Thioglycolates
  • Mechanism of Action Peptidyltransferase modulators; Protein 50S ribosomal subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia
  • Phase II Skin and soft tissue infections
  • Preclinical Bacterial infections; Bone and joint infections; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections

Most Recent Events

  • 20 Sep 2017 Adverse events and efficacy data from the phase III LEAP 1 trial in Community-acquired pneumonia released by Nabriva Therapeutics
  • 01 May 2017 Nabriva completes a phase III trial in Community-acquired pneumonia in Argentina, Brazil, Russia, South Africa, Thailand, USA, Bosnia and Herzegovina, Latvia, Bulgaria, Hungary, Georgia and Netherlands, Peru, Philippines, Poland, Romania, Serbia and Ukraine (IV) (PO) (NCT02559310)
  • 22 Apr 2017 Antimicrobial data from a preclinical study in Bacterial infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (CMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top